P59. Depleting the suppressors for the benefit of immunotherapy against cervical cancer

Background Cancer vaccines aim at inducing tumour-specific immune responses. However, in clinical studies so far these approaches have limited antitumour effect. Evidence is accumulating that MDSC (myeloid-derived suppressor cells) can suppress the antitumour immune response. Reversal of MDSC-mediated immune suppression by treatment with the tyrosine kinase inhibitor sunitinb can therefore possibly increase the efficacy of cancer vaccines.